Heterocyclic derivatives of DTPA used for magnetic resonance imaging
AssigneeSalutar, Inc.
InventorsWilliam P. Cacheris, Stephen C. Quay
Life of this patent
Estimating the term…
Abstract
Gadolinium and calcium chelates of DTPA (diethylenetriaminepentaacetic acid) bisamides, such as a composition comprising a gadolinium chelate of a 6-carboxymethyl-3,9-bis (hydroxyalkyl-carbamoylmethyl)-3,6,9-triazaundecanedioic acid and a calcium chelate of a 6-carboxymethyl-3,9-bis(hydroxyalkyl-carbamoylmethyl)-3,6,9- triazaundecanedioic acid, are disclosed for use as magnetic resonance imaging contrast media.
Claims26
A magnetic resonance imaging contrast medium comprising a gadolinium chelate of a compound of formula I:
- ##STR5## wherein R.sub.1 and R.sub.2 are independently C.sub.1-6 hydroxyalkyl and R.sub.3 and R.sub.4 are independently hydrogen or C.sub.1-6 alkyl, or NR.sub.1 R.sub.3 and NR.sub.2 R.sub.4 are independently a cyclic group of formula:
- ##STR6## wherein R.sub.5 represents hydrogen, hydroxy or C.sub.1-6 hydroxy- or alkoxy-substituted alkyl, n is 0, 1 or 2 and X is CHR.sub.5, NR.sub.5, oxygen or sulfur, with the proviso that at least one of NR.sub.1 R.sub.3 and NR.sub.2 R.sub.4 is a said cyclic group, and a toxicity reducing amount of a calcium chelate of a compound of formula I.
In a method of magnetic resonance imaging of a human or non-human animal subject, the improvement comprising administering to said subject a contrast effective amount of a contrast medium comprising a gadolinium chelate of a compound of formula I:
- ##STR7## wherein R.sub.1 and R.sub.2 are independently C.sub.1-6 hydroxyalkyl and R.sub.3 and R.sub.4 are independently hydrogen or C.sub.1-6 alkyl, or NR.sub.1 R.sub.3 and NR.sub.2 R.sub.4 are independently a cyclic group of formula:
- ##STR8## wherein R.sub.5 represents hydrogen, hydroxy or C.sub.1-6 hydroxy- or alkoxy-substituted alkyl, n is 0, 1 or 2 and X is CHR.sub.5, NR.sub.5, oxygen or sulfur, with the proviso that at least one of NR.sub.1 R.sub.3 and NR.sub.2 R.sub.4 is a said cyclic group, and a toxicity reducing amount of a calcium chelate of a compound of formula I.
Dependencies are inferred from the claim text.